3,4-methylene-dioxy-pyrovalerone (MDPV) epidemic?;3,4-metilén-dioxi-pirovaleron-(MDPV-) epidémia?

Orvosi Hetilap

Volumn 152, Issue 50, 2011, Pages 2010-2019

  Kalapos, Miklós Péter ^a  

^a Elméleti Biológiai Kutatócsoport ^*  (Hungary)

Author keywords

3,4 methylene dioxy pyrovalerone (MDPV); catechol; CYP2C19; designer drug; disturbance of perception; hypersomnia; increase of vigilance; panic attack

Indexed keywords

3,4 METHYLENE DIOXY PYROVALERONE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESIGNER DRUG; GLUCURONIC ACID; ILLICIT DRUG; SULFATE; UNCLASSIFIED DRUG;

ALERTNESS; ARTICLE; BONE PAIN; CATALYST; DRUG ABUSE; DRUG CONJUGATION; DRUG INTOXICATION; DRUG METABOLISM; DRUG WITHDRAWAL; EPIDEMIC; HYPERSOMNIA; MYALGIA; PERCEPTION DISORDER; PROTEIN FUNCTION; VISUAL DISORDER;

ARYL HYDROCARBON HYDROXYLASES; BENZODIOXOLES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; DESIGNER DRUGS; HUMANS; HUNGARY; PSYCHOTROPIC DRUGS; PYRROLIDINES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 82455174383     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29259     Document Type: Article

References (23)

1. Kalapos M. P.: A biotranszformáció konjugáció s enzimeinek farmakogenetikája. Psychiatria Hungarica, 2004, 19, 310-318.
2. Kalapos M. P.: Bevezetés az addiktológiába. Medicina Könyv-kiadó, Budapest, in press.
3. Gouzoulis-Mayfrank, E., Hermle, L., Kovar, K. A. és mtsa: Die Entaktogene "Ecstasy" (MDMA), "Eve" (MDE) und andere ringsubstituirte Methamphetaminderivate. Nervenartz, 1996, 67, 369-380. (Pubitemid 26174847)
4. Maurer, H. H., Kraemer, T., Springer, D. és mtsa: Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of amphetamine (Ecstasy), piperazine, and pyrolidinophe-none types. A synopsis. Ther. Drug Monit., 2004, 26, 127-131. (Pubitemid 38501205)
5. Kalapos M. P.: Bevezetés az alkohológiába. Medicina Könyv-kiadó, Budapest, 2007.
6. Meyer, U. A.: Genotype or phenotype: the definition of a phar-macogenetic polymorphism. Pharmacogenetics, 1991, 1, 66-67.
7. Leeder, J. S.: Pharmacogenetics and pharmacogenomics. Pediatr. Clin. North Am., 2001, 48, 765-781. (Pubitemid 32521715)
8. Fehér J., Vereczkei A.: Szabadgyök-reakciók jelentosége az orvos-tudományban. Biogal Gyó gyszergyár, Debrecen, 1985.
9. Yohannan, J. C., Bozenko, J. S. Jr.: The characterization of 3.4-methylenedioxypyrovalerone (MDPV). Microgram J., 2010, 7, 12-15.
10. Meltzer, P. C., Butler, D., Deschamps, J. R. és mtsa: 1-(4-me thyl-phenyl)-2-pyrrolidin-1-yl-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49, 1420-1432. (Pubitemid 43271895)
11. Westphal, F., Junge, T., Rösner, P. és mtsai: Mass and NMR spectroscopic characterization of 3.4-methylenedioxypyrovale-rone: A designer drug with α-pyrrolidinophenone structure. Forensic. Sci. Intern. 2009, 190, 1-8.
12. Ojanperä, I. A., Heikman, P. K., Rasanen, I. J.: Urine analysis of 3.4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther. Drug Monit., 2011, 33, 257-263.
13. Kim, H. S., Aftab, A., Shah, M. és mtsa: Physical and psychological effects of new legal high "Ivory Wave": a case report. Br. J. Med. Praction., 2010, 3, a343
14. Kriikku, P., Wilhelm, L., Schwarz, O. és mtsa: New designer drug of abuse: 3.4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic. Sci. Int., 2011, 210, 195-200
15. Strano-Rossi, S., Cadwallader, A. B., de la Torre, X. és mtsa: Toxi-cological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatog-raphy/mass spectrometry and liquid chromatography/quadru-pole time-off-flight mass spectrometry. Rapid Commun. Mass Spectrom., 2010, 24, 2706-2714.
16. Meyer, M. R., Du, P., Schuster, F. és mtsa: Studies on the metabolism of the α-pyrrolinidophenone designer drug methylenedioxy- pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high resolution MS and its detectability in urine by GC-Ms. J. Mass Spectrom., 2010, 45, 1426-1442
17. The Merck Index. Ed.: Budavári, S. 11th edition. Merck and Co., Inc., Rahway, N. J., USA, 1999.
18. Bazire, S.: Psychotropic Drug Directory 2005. Organon and Fivepin Publishing, Salisbury, United Kingdom, 2005.
19. Vereczkey, L., Jemnitz, K., Monostory, K.: Human liver cy-tochrome P-450 and conjugating enzymes. Hungarian data. Acta Physiol. Hung., 1997/98, 85, 149-152. (Pubitemid 128500297)
20. Billings, R.: Mechanism of catechol formation from aromatic compounds in isolated rat hepatocytes. Drug Metab. Dispos., 1985, 13, 287-290. (Pubitemid 15009443)
21. Kappus, H.: Overview of enzyme systems involved in bioreduc-tion of drugs and in redox cyclings. Biochem. Pharmacol., 1986, 35, 1-6 (Pubitemid 16161353)
22. Benzie, F., Hekman, K., Cameron, L. és mtsai: Emergency Department Visits After Use of a Drug Sold as "Bath Salts"-Michigan, November 13, 2010-March 31, 2011. Morbidity and Mortality Weekly Report 624 MMWR (May 20, 2011), 2011, 60, 624-627.-website (http://www.cdc.gov/mmwr).
23. Stöcker G.: Kísérleti nyulak az új drogok fogyasztói. Index, 2011. augusztus 12.